Cycloheximide (CHX) is frequently employed in proteasomal degradation research because it non‐selectively inhibits protein biosynthesis within cells.[55] Following treatment with CHX, GLO1 knockdown accelerated the degradation of GSS in breast cancer cell lines, and this effect was reversed when MG132 (a proteasome inhibitor) was added to the breast cancer cell lines (Figure 8O). The gene discussed is GLO1; the disease is breast carcinoma.